[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cerebrovascular-disorders\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cerebrovascular-disorders":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,40,0,25,[9,55,96,128,149,178,213,242,271,298,326,356,390,413,450,473,504,525,554,580,608,635,666,694,714],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":38,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100644087","efficacy-and-safety-of-antihypertensive-treatment-with-mobile-stroke-units-in-ultra-early-intracerebral-hemorrhage-100644087",false,"NCT07665827","Efficacy and Safety of Antihypertensive Treatment With Mobile Stroke Units in Ultra-Early Intracerebral Hemorrhage","Efficacy and Safety of Antihypertensive Treatment With Mobile Stroke Units in Ultra-Early Intracerebral Hemorrhage: A Multicenter, Prospective, Cluster-Randomized, Open-Label, Blinded-Endpoint Clinical Trial","MSU-ICH","Inclusion Criteria:\n\n1. History and physical\u002Fneurological examination consistent with acute stroke.\n2. Age ≥18 years;\n3. Time from symptom onset to enrollment \\\u003C3 hours (onset defined as last known normal).\n4. Systolic blood pressure ≥150 mmHg and ≤220 mmHg;\n5. Pre-stroke modified Rankin Scale (mRS) score ≤2;\n6. Informed consent obtained from the subject or a legally authorized representative.\n\nExclusion Criteria:\n\n1. Glasgow Coma Scale (GCS) score ≤5.\n2. Contraindications to intensive blood pressure lowering, including severe arterial stenosis or high-grade stenotic valvular heart disease.\n3. Malignant disease or other serious primary illness with a life expectancy of \\\u003C3 months.\n4. Current participation in another interventional randomized clinical trial.","ALL","18 Years",{"count":21,"type":22},706,"ESTIMATED","INTERVENTIONAL",[25],"NA","MSU-ICH is a prospective, multicenter, Week-wise-randomized, open-label, blinded-endpoint (PROBE) clinical trial comparing ultra-early prehospital blood pressure lowering delivered by a Mobile Stroke Unit (MSU) with standard Emergency Medical Services (EMS) in patients with spontaneous intracerebral hemorrhage.",[28,29,30,31,32,33,34,35,36,37],"Nervous System Diseases","Cerebrovascular Disorders","Cardiovascular Diseases","Vascular Diseases","Hemorrhage","Intracranial Hemorrhages","Cerebral Hemorrhage","Cerebral Hemorrhage, Hypertensive","Stroke","Hemorrhagic Stroke, Intracerebral",[39,40,41],"intracerebral hemorrhage","mobile stroke units","Intensive blood pressure lowering","NOT_YET_RECRUITING","2026-06-18",{"date":45,"type":46},"2026-06-24","ACTUAL",{"date":48,"type":22},"2026-06",{"date":50,"type":22},"2028-07",{"name":52,"class":53},"Xuanwu Hospital, Beijing","OTHER",1,{"id":56,"slug":57,"hasResults":12,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":63,"targetDuration":4,"studyType":23,"phases":65,"briefSummary":66,"conditions":67,"keywords":75,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":95},"100641032","effectiveness-of-best-care-practices-in-acute-stroke-in-conventional-hospitalization-best-care-ictushc-100641032","NCT07627399","Effectiveness of Best Care Practices in Acute Stroke in Conventional Hospitalization (BEST CARE ICTUS_HC)","Effectiveness of Implementing Best Care Practices in the Management of Patients With Acute Stroke in Conventional Hospitalization: A Cluster-Randomized, Open, Stepped-Wedge Controlled Trial.","BESTCAREICTUS","Inclusion Criteria:\n\n* Patients aged 18 years or older.\n* Clinical diagnosis of acute ischemic or hemorrhagic stroke.\n* Admission to conventional hospitalization units (Internal Medicine) in regional hospitals without specialized Stroke Units.\n\nExclusion Criteria:\n\n* Patients admitted for a cause other than stroke who develop a stroke during their hospital stay (in-hospital stroke).\n* Patients subjected to invasive neurological procedures.\n* Patients undergoing invasive procedures, such as thrombectomy, who require transfer to a referral hospital and remain there for more than 48 hours.\n* Patients with deterioration of the level of consciousness that prevents the performance of dysphagia testing.\n* Patients that have been taken care of by Nurses and Nursing Assistants with \\>4 weeks of work experience in Stroke Units in the last 12 months",{"count":64,"type":22},700,[25],"The goal of this clinical trial is to evaluate whether a multicomponent nurse-led intervention (BEST CARE ICTUS\\_HC) can reduce stroke-related complications and improve recovery in adults (18 years and older) hospitalized with an acute ischemic or hemorrhagic stroke in hospitals without specialized Stroke Units. The main questions it aims to answer are:\n\n1. Does the implementation of the program increase the early and correct detection of swallowing difficulties (dysphagia) to prevent pneumonia?\n2. Does the program reduce the severity of attention problems (hemineglect) and improve the patients' quality of life up to 6 months after discharge?\n\nResearchers will compare patients receiving the BEST CARE ICTUS\\_HC program to patients receiving usual hospital care to see if this new approach improves patient safety and long-term functional recovery.\n\nParticipants will:\n\n* Receive either the usual hospital care for stroke or the BEST CARE ICTUS\\_HC nursing program, depending on the study phase of the hospital.\n* Be screened for swallowing problems using a standardized test before receiving any food or drink.\n* Be cared for in an adapted environment (FLECHA Project) that uses visual signs and room organization to help with orientation and safety.\n* Have their temperature, blood sugar, and blood pressure monitored under a strict specialized protocol.\n* Be contacted by phone 30 days and 6 months after leaving the hospital to answer questions about their health and quality of life.",[36,68,69,70,29,71,72,73,74],"Acute Stroke","Ischemic Stroke","Hemorrhagic Stroke","Deglutition Disorders","Perceptual Disorders","Unilateral Neglect","Pneumonia, Aspiration",[68,76,77,73,78,79,80,81,82,83,84],"Nursing Care","Dysphagia Screening","Multicomponent Intervention","Care Bundle","Stepped-Wedge Design","Deglutition","Quality of life","Hyperglycemia","Fever","RECRUITING","2026-05-29",{"date":88,"type":46},"2026-06-04",{"date":90,"type":46},"2026-05-12",{"date":92,"type":22},"2028-12",{"name":94,"class":53},"University of Malaga",4,{"id":97,"slug":98,"hasResults":12,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":23,"phases":105,"briefSummary":108,"conditions":109,"keywords":113,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":127},"100507832","phase-2-post-thrombectomy-intra-arterial-tenecteplase-for-acute-management-of-non-retrievable-thrombus-and-no-reflow-in-emergent-stroke-100507832","NCT05892510","Post-thrombectomy Intra-arterial Tenecteplase for Acute manaGement of Non-retrievable Thrombus and No-reflow in Emergent Stroke","Post-thrombectomy Intra-arterial Tenecteplase for Acute manaGement of Non-retrievable Thrombus and No-reflow in Emergent Stroke (EXTEND-AGNES TNK)","Inclusion Criteria:\n\n* Adult participants (age≥18 years) presenting with ischemic stroke with arterial LVO on CT\u002FMR Angiogram of the intracranial internal carotid or middle cerebral artery (MCA) first segment (M1) or proximal second segment (M2) committed to thrombectomy using standard criteria within 24 hours of onset:\n* For 0-6 hours of symptom onset: Presence of arterial occlusion as defined above and ASPECTS≥3 on NCCT\n* For 6-24 hours of symptom onset: Additional imaging criteria on CTP or MRI perfusion of core volume \\\u003C100ml.\n* Qualifying CT\u002FMR within 4hrs of randomisation (repeat CT for transferred participants required if \\>4hr)\n* Pre-stroke Modified Rankin Scale (mRS) score of ≤2 (mild pre-existing disability permitted)\n* Local legal requirements for consent have been satisfied.\n\nExclusion Criteria:\n\n* Intracranial hemorrhage identified by CT or MRI\n* ASPECTS 0-2 on NCCT\n* CTP or MRI perfusion ischemic core volume \\>100ml if presenting within 6-24 hours from symptoms onset\n* Anticipated endovascular stenting required for intracranial or extracranial atherosclerotic stenosis\u002Focclusion.\n* More than six retrieval attempts in the same vessel\n* Alteplase being infused within 30 minutes (\\~5x half-life) of anticipated trial drug administration\n* Contraindication to imaging with contrast agents\n* Any condition (eg.mid-arterial phase early venous filling) that in the judgment of investigators could impose hazards if study therapy is initiated\n* Pregnant women.\n* Current participation in another intervention research study that includes experimental interventions beyond standard-of-care.\n* Anticoagulation. INR ≤1.7 if on warfarin, and dabigatran reversal by idarucizumab are permitted.\n* Other standard contraindications to thrombolysis apart from time window.\n* Known terminal illness such that the participants would not be expected to survive a year.\n* Planned withdrawal of care or comfort care measures.",{"count":104,"type":22},462,[106,107],"PHASE2","PHASE3","Multicentre, prospective, Multi-arm Multi-stage (MAMS) seamless phase 2b\u002F3 interventional randomized placebo-controlled double-blinded parallel-assignment (2 arms with 1:1 randomization) efficacy and safety trial to test intra-arterial tenecteplase at the completion of thrombectomy versus best practice in participants with anterior circulation LVO receiving mechanical thrombectomy within 24 hours of symptoms onset.",[110,29,111,112],"Ischemic Stroke, Acute","Brain Disorder","Central Nervous System Diseases",[114,115,116,117],"Tenecteplase","Fibrinolytic agents","Thrombectomy","No-reflow","2026-05-14",{"date":120,"type":46},"2026-05-18",{"date":122,"type":46},"2024-06-01",{"date":124,"type":22},"2027-11-30",{"name":126,"class":53},"University of Melbourne",12,{"id":129,"slug":130,"hasResults":12,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":23,"phases":137,"briefSummary":138,"conditions":139,"keywords":4,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":54},"100559941","video-call-assisted-assessment-of-acute-stroke-100559941","NCT06570681","Video Call Assisted Assessment of Acute Stroke","Video Call Assisted Assessment of Acute Stroke in Addition to Stroke Scales in a Prehospital Setting: A Cluster Randomised Controlled Trial","Inclusion Criteria:\n\n* Suspected stroke within 24 hours from onset (confirmed with Prehospital Stroke 1 decision tool)\n* Age \\>18 years\n\nExclusion Criteria:\n\n* Suspected stroke more than 24 hours ago\n* In-hospital stroke or private transport to hospital\n* Unconsciousness defined as Glasgow Coma Score (GCS) ≤ 8 (as they cannot be rated)",{"count":136,"type":22},512,[25],"This study aims to investigate whether a live stream video between the on-call neurologist and the emergency medical technicians can increase feasibility and performance of symptom-based prehospital stroke scales.",[36,29,140,28,31,112],"Brain Diseases","2026-05-11",{"date":118,"type":46},{"date":144,"type":46},"2024-05-27",{"date":146,"type":22},"2026-06-03",{"name":148,"class":53},"University of Southern Denmark",{"id":150,"slug":151,"hasResults":12,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":155,"eligibilityCriteria":156,"healthyVolunteers":157,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":158,"targetDuration":4,"studyType":23,"phases":160,"briefSummary":161,"conditions":162,"keywords":163,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":54},"100599402","home-based-cognitive-strategy-training-for-daily-living-in-adults-with-chronic-stroke-100599402","NCT07084025","Home-based Cognitive Strategy Training for Daily Living in Adults With Chronic Stroke","Feasibility of Home-based Cognitive Strategy Training for Independence of Activities of Daily Living in Adults With Chronic Stroke","PRPP-HOME","Patient's Main Eligibility criteria:\n\n* Adult over 18 years of age;\n* cognitive deficits (or Acquired Brain Injury) diagnosed due to ischemic or hemorrhagic, hemispheric or brainstem stroke, confirmed by brain imaging longer than 6 months;\n* Patient with mild (\\\u003C26\u002F30 or \\\u003C25\u002F30 for patients aged 71-85 yr) or moderate (\\[18-25\\]\u002F30) cognitive impairment, measured by the Montreal Cognitive Assessment test ;\n* adults living in a home or community-based setting;\n* Patient with a non-professional caregiver;\n\nPatient's Main Exclusion criteria\n\n* Neurological pathology other than stroke or psychiatric disorder;\n* Significant cognitive impairment, according to MoCA score \\\u003C18\u002F30;\n* Patient with severe aphasia, Boston Diagnostic Aphasia Examination score \\>2",true,{"count":159,"type":22},18,[25],"This pilot experimental study aims to describe the feasibility of a cognitive strategy training protocol : PRPP-I, in activities of daily life across home-based setting for adults with chronic stroke for improvement of independence and quality of life. Aditionnally to examine preliminary effectiveness of PRPP-I protocol within a home-based setting on functional cognitive strategies, independence, quality of life and career burden.",[36,29],[164,165,166,167,168],"Cognitive strategy training","Task-based","Ecological","Performance","Activities of Daily Living","2026-05-07",{"date":171,"type":46},"2026-05-08",{"date":173,"type":46},"2026-01-05",{"date":175,"type":22},"2027-12-31",{"name":177,"class":53},"University Hospital, Toulouse",{"id":179,"slug":180,"hasResults":12,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":184,"eligibilityCriteria":185,"healthyVolunteers":12,"sex":186,"minAge":187,"maxAge":188,"enrollmentInfo":189,"targetDuration":191,"studyType":192,"phases":4,"briefSummary":193,"conditions":194,"keywords":196,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":211,"locationsCount":54},"100530456","hypertension-explored-in-long-term-postpartum-follow-up-in-later-life-100530456","NCT06187012","Hypertension Explored in Long-term Postpartum Follow-up in Later Life","Hypertension Explored in Long-term Postpartum Follow-up in Later Life (HELPFUL)","HELPFUL","Inclusion Criteria:\n\n* Inclusion Criteria\n\n  * Participant is willing and able to give informed consent for participation in the study\n  * Female who had a pregnancy 10 to 25 years prior\n  * Able (in the investigator's opinion) and willing to comply with all study requirements.\n  * Adequate understanding of verbal and written English\n\nExclusion Criteria:\n\n* The participant may not enter the study if ANY of the following apply:\n\n  * Over 10 weeks pregnant during the course of the study\n  * Evidence of congenital heart disease or significant chronic disease relevant to cardiovascular or metabolic status\n  * Any significant disease or disorder which, in the opinion of the investigator, might influence the participant's ability to participate in the study\n\nFor exclusion of MRI component only:\n\n• Unsuitable for MRI based on the responses to the MRI screening form. The participant may still be included in other parts of the study.","FEMALE","30 Years","70 Years",{"count":190,"type":22},200,"40 Years","OBSERVATIONAL","The purpose of this study is to understand more about why women who have had hypertensive pregnancies may be at increased risk of high blood pressure and why these women are often at increased risk of heart and blood vessel disease later in life.",[195,30,29,31],"Hypertension",[197,198,199,200,201,202,203],"Hypertensive pregnancy","Older adults","Pre-eclampsia","Gestational hypertension","Cardiovascular risk","Disease progression","Longitudinal","2026-04-28",{"date":206,"type":46},"2026-04-29",{"date":208,"type":46},"2023-03-23",{"date":210,"type":22},"2042-11-01",{"name":212,"class":53},"University of Oxford",{"id":214,"slug":215,"hasResults":12,"nctId":216,"briefTitle":217,"officialTitle":218,"acronym":219,"eligibilityCriteria":220,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":221,"enrollmentInfo":222,"targetDuration":4,"studyType":23,"phases":224,"briefSummary":226,"conditions":227,"keywords":229,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":241},"100506224","phase-1-inhaled-nitric-oxide-in-acute-ischemic-stroke-patients-undergoing-mechanical-thrombectomy-100506224","NCT05871606","Inhaled Nitric Oxide in Acute Ischemic Stroke Patients Undergoing Mechanical Thrombectomy","Inhaled Nitric Oxide in Acute Ischemic Stroke Patients Undergoing Mechanical Thrombectomy: A Phase I Drug Pilot Research Plan","iNO","Inclusion Criteria:\n\n* Age 18 and \\\u003C 80\n* Clinical evidence of acute ischemic (non-bleeding) stroke (AIS) with NIH Stroke Scale of 6 or higher\n* Non-contrast Computed tomography (CT) Head with ASPECT (Alberta Stroke Program Early CT) score 6\n* Symptom onset began \\\u003C 16 hours from initiation of intra-arterial mechanical thrombectomy (IAMT) procedure\n* CT Angiogram (CTA) evidence of anterior circulation MCA (Middle Cerebral Artery) M1 or dominant proximal M2 segment occlusion.\n* CT Perfusion (CTP) evidence of core infarct volume of \\\u003C 70ml and a ratio of ischemic tissue to initial core infarct volume of 1.8 or greater, and an absolute volume of penumbra of 15ml or greater\n* Patient or patient's representative provides consent\n* Pre-stroke modified Rankin Scale (mRS) of \\\u003C =2\n* General endotracheal anesthesia (GETA) is planned to be used, as standard care, for IAMT\n* Treatment with iNO requires mechanical ventilation. Because IAMT can be performed using conscious sedation and not GETA, only those patients for which the procedure is planned with GETA will be included. The decision for the type of anesthetic depends on the severity of stroke, region of brain affected by the stroke, and the ability for the patient to cooperate for the procedure.\n\nExclusion Criteria:\n\n* Hypotension at presentation, defined as systolic blood pressure (SBP) \\\u003C 100 or MAP \\\u003C 60; profound hypertension with SBP \\>185 or DBP \\>110mmHg unable to be controlled with IV medications\n* Inability to undergo a brain MRI (e.g., implanted pacemaker)\n* Patients who received IV tPA \\>4.5hrs after symptom onset\n* Coaguloapathy, defined as platelet count \\\u003C 50,000, INR \\>3.0, PTT \\> 3x normal, use of novel anticoagulants with eGFR \\\u003C 30ml\u002Fmin\n* Vulnerable Subjects including: mentally ill or incompetent patients, those with diminished decision-making capacity, prisoners, inpatient care for long-term chronic illness, terminally ill, pregnant women, and children\n* Any form of hemorrhage on non-contrast CT Head or mass lesion\n* Severe head injury within 90 days\n* Pre-existing severe neurological\u002Fpsychiatric disease\n* Seizure at stroke onset (unable to assess NIHSS)\n* Blood glucose \\\u003C 50mg\u002FdL or \\>400mg\u002FdL\n* Hemoglobin \\\u003C7mmol\u002FL\n* eGFR \\\u003C 30ml\u002Fmin\n* Allergy to contrast media\n* Presumed septic embolus as source of stroke\n* Flow limiting intracranial or extracranial carotid stenosis, or complete carotid occlusion","80 Years",{"count":223,"type":22},36,[225],"PHASE1","The purpose of this study is to determine the safety and feasibility of using inhaled nitric oxide (iNO) in patients undergoing intra-arterial mechanical thrombectomy (blood clot extraction or IAMT) for treatment of acute ischemic (non-bleeding) stroke (AIS).",[29,228],"Acute Cerebrovascular Disease",[36,230,231],"blood clot extraction","large vessel occlusion","2026-04-22",{"date":234,"type":46},"2026-04-23",{"date":236,"type":46},"2026-04-16",{"date":238,"type":22},"2028-12-01",{"name":240,"class":53},"Wake Forest University Health Sciences",2,{"id":243,"slug":244,"hasResults":12,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":248,"eligibilityCriteria":249,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":250,"targetDuration":4,"studyType":23,"phases":252,"briefSummary":253,"conditions":254,"keywords":257,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":264,"completionDateStruct":266,"leadSponsor":268,"locationsCount":270},"100607166","intra-arterial-thrombolysis-for-acute-ischemic-stroke-with-medium-vessel-occlusion-100607166","NCT07185022","Intra-arterial Thrombolysis for Acute Ischemic Stroke With Medium Vessel Occlusion","a Multicenter Prospective Randomized Controlled Trial of Intra-artErial thrombolysiS for aCUte Ischemic strokE With Medium Vessel Occlusion (RESCUE MeVO)","RESCUE MeVO","Inclusion Criteria:\n\n* Age \\> 18 years\n* Primary medium vessel occlusion (MeVO) or severe stenosis (≥70%) was detected on CTA, MRA, or DSA, involving arterial segments including M2-M3 of the middle cerebral artery (MCA), A1-A2 of the anterior cerebral artery (ACA), P1-P2 of the posterior cerebral artery (PCA), and the anterior inferior cerebellar artery (AICA), posterior inferior cerebellar artery (PICA), and superior cerebellar artery (SCA)\n* The clinical symptoms were consistent with MeVO, with a NIHSS score 5 - 25, or an NIHSS score of 3-4 in the presence of disabling neurological deficits (e.g., hemianopia, aphasia, or motor dysfunction)\n* Intra-arterial thrombolysis was administered within the following time windows:\n\n  1. Acute ischemic stroke within 24 hours of symptom onset or last known well, including stroke with known onset, wake-up stroke and stroke with unknown onset, with no obvious hypodensity on CT and good collateral circulation on CTA;\n  2. Acute ischemic stroke within 24-72 hours of onset, meeting at least one of the following imaging criteria: a.CT or MR perfusion imaging demonstrating target mismatch, defined as an ischemic core volume \\\u003C30 mL, a mismatch ratio ≥1.2, and a mismatch volume ≥10 mL.; b.MRI demonstrating DWI-FLAIR mismatch, defined as the presence of acute ischemic lesions on diffusion-weighted imaging (DWI) with no corresponding hyperintense signal on FLAIR, or with FLAIR hyperintense lesions occupying less than one-third of the DWI lesion volume.\n* Signed informed consent obtained\n\nExclusion Criteria:\n\n* Pre-stroke mRS ≥ 2\n* Secondary MeVO or severe stenosis caused by endovascular therapy\n* Neuroimaging demonstrated intracranial hemorrhage, subarachnoid hemorrhage, or other hemorrhagic disorders\n* Non-contrast CT demonstrating a clearly hypodense lesion corresponding to the vascular territory\n* Platelet count \\\u003C100 × 10⁹\u002FL, known bleeding tendency or coagulation factor deficiency, or oral anticoagulant therapy with an international normalized ratio (INR) \\>3.0\n* Persistent and uncontrolled hypertension, defined as systolic blood pressure \\>185 mmHg or diastolic blood pressure \\>110 mmHg\n* History of intracranial hemorrhage within the past 3 months, including parenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, epidural hemorrhage, or subdural hemorrhage\n* Presence of arteriovenous malformations or brain tumors with mass effect\n* Gastrointestinal or urinary tract bleeding, or major surgery within the past 3 months\n* Chronic dialysis or severe renal impairment, defined as a glomerular filtration rate (GFR) \\\u003C30 mL\u002Fmin or serum creatinine \\>220 μmol\u002FL (2.5 mg\u002FdL)\n* Patients with known allergy to thrombolytic agents or their excipients\n* Patients with known allergy to iodinated contrast agents or other established contraindications\n* Pregnant or current breastfeeding\n* Presence of severe systemic comorbidities with a life expectancy of less than 3 months\n* Deemed unsuitable for participation by the investigator for any reason",{"count":251,"type":22},282,[25],"Acute ischemic stroke (AIS) due to medium vessel occlusion (MeVO) or severe stenosis poses a significant clinical challenge. Recent large randomized controlled trials, DISTAL and ESCAPE-MeVO, demonstrated no significant benefit of endovascular therapy in patients with MeVO. Although intra-arterial thrombolysis has shown promise in clinical experience, robust evidence supporting its efficacy in MeVO or severe stenosis-related AIS is still absent. To fill this gap, the RESCUE MeVO trial has been designed as a multicenter, prospective, randomized, open-label, blinded end-point (PROBE) study to evaluate the efficacy and safety of intra-arterial thrombolysis in patients with AIS caused by MeVO or severe stenosis.",[36,29,140,28,31,69,255,256],"Infarction","Medium Vessel Occlusion",[258,259,36,260,261],"Ischemic stroke","Medium vessel occlusion","Intra-arterial thrombolysis","Severe stenosis","2026-04-13",{"date":236,"type":46},{"date":265,"type":46},"2026-01-06",{"date":267,"type":22},"2030-05-01",{"name":269,"class":53},"The Second Hospital of Anhui Medical University",6,{"id":272,"slug":273,"hasResults":12,"nctId":274,"briefTitle":275,"officialTitle":276,"acronym":277,"eligibilityCriteria":278,"healthyVolunteers":157,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":279,"targetDuration":4,"studyType":23,"phases":281,"briefSummary":282,"conditions":283,"keywords":287,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":290,"lastUpdatePostDateStruct":291,"startDateStruct":292,"completionDateStruct":294,"leadSponsor":296,"locationsCount":54},"100330747","neuropsychological-and-brain-medical-imaging-study-in-patients-with-brain-damage-2-100330747","NCT03586258","Neuropsychological and Brain Medical Imaging Study in Patients With Brain Damage 2","Anatomical Clinical Correlations. Neuropsychological and Brain Medical Imaging Study in Brain Damage Subjects 2 (CORAC2)","CORAC2","Inclusion Criteria:\n\n* Age \\> 17 years\n* French language\n* Effective contraception for women during the study\n* Informed consent\n* No alcohol intake the day before the exam\n* For patients only, focal cerebral lesion (stroke, malformation, tumor, inflammatory, infectious, traumatic), neonatal pathology, developmental or degenerative disease with cognitive deficit\n\nExclusion Criteria:\n\n* For healthy volunteers: previous neurological history (except non complicated migraine or epilepsy), previous psychiatric history (except depression with good evolution or anxiety), or severe cranial traumatism\n* For patients: vigilance disorders, severe depression or anxiety.\n* For both: psychotropic medication other than a hypnotic or an anxiolytic at low doses without dose modification for at least one month, severe visual or auditory impairment, patient without judicial or administrative liberty, measure of legal protection or no capable to express their consent, pregnancy or breastfeeding, contraindication for MRI or GVS if applicable, participation in another trial or former involvement in another trial within one month.",{"count":280,"type":22},400,[25],"Two groups of subjects will be constitute: (i) patients with circumscribed brain injury (including stroke, vascular malformations, tumor or circumscribed infectious lesions) or degenerative\u002Fdevelopmental disorders and selective cognitive disorders; (ii) healthy control subjects.\n\nThe objective of this project is to evaluate specific neuropsychological deficits and apply current brain imaging techniques (anatomical, diffusion, functional, magnetic stimulation) to patients suffering from these cognitive deficits due to brain damage, in order to elucidate the brain mechanisms underlying these deficits.",[29,284,285,286],"Brain Lesion","Degenerative Disease","Developmental Disability",[288,289],"Neuropsychological study","Brain imaging","2026-04-09",{"date":262,"type":46},{"date":293,"type":46},"2019-01-10",{"date":295,"type":22},"2030-06",{"name":297,"class":53},"University Hospital, Caen",{"id":299,"slug":300,"hasResults":12,"nctId":301,"briefTitle":302,"officialTitle":303,"acronym":4,"eligibilityCriteria":304,"healthyVolunteers":12,"sex":18,"minAge":305,"maxAge":221,"enrollmentInfo":306,"targetDuration":4,"studyType":23,"phases":308,"briefSummary":309,"conditions":310,"keywords":311,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":317,"lastUpdatePostDateStruct":318,"startDateStruct":320,"completionDateStruct":322,"leadSponsor":324,"locationsCount":54},"100508654","mixed-reality-and-virtual-reality-technology-with-mirror-therapy-for-stroke-rehabilitation-100508654","NCT05903235","Mixed Reality and Virtual Reality Technology With Mirror Therapy for Stroke Rehabilitation","Technology-based and Activity-based Design of Mirror Therapy Principles: Two Mixed Reality and Virtual Reality Mirrored-hand Systems for Stroke Rehabilitation","Phase Ⅰ: Design and Development of the VR+MT and MR+MT Systems \\& Feasibility Study\n\nInclusion Criteria:\n\n* diagnosed with unilateral stroke\n* age of 20 to 80 years\n* a baseline Fugl-Meyer Assessment of the Upper Extremity score of 20 to 60\n* able to follow the study instructions and provide the feedback of user experiences verbally\n\nExclusion Criteria:\n\n* diagnosed with global or receptive aphasia\n* the presence of severe neglect\n* the existence of major medical problems or comorbidities that could interfere with upper-limb usage and pain, or disrupt visual or auditory perception\n\nPhase Ⅱ: Validation and Comparison of Clinical Treatment Efficacy\n\nInclusion Criteria:\n\n* diagnosed with unilateral stroke\n* more than 6 months after stroke onset\n* age of 20 to 80 years\n* a baseline Fugl-Meyer Assessment of the Upper Extremity score of 20 to 60\n* able to follow the study instructions\n* capable of participating in the assessment process and treatment program\n\nExclusion Criteria:\n\n* diagnosed with global or receptive aphasia\n* the presence of severe neglect\n* the existence of major medical problems or comorbidities that could interfere with upper-limb usage and pain, or disrupt visual or auditory perception","20 Years",{"count":307,"type":22},45,[25],"The specific study aims will be:\n\n1. To design and develop the hardware and software of the VR+MT and MR+MT systems.\n2. To test the feasibility of the VR+MT and MR+MT systems from the patients and to collect the feedback of users with respect to their experiences.\n3. To examine the treatment effects of VR+MT and MR+MT compared to the traditional MT (i.e., control group) in patients with stroke by conducting a randomized controlled trial.\n4. To identify who will be the possible good responders to VR+MT and MR+MT based on their baseline motor functions and mental imagery abilities.",[36,29,112],[312,313,314,315,316],"digital rehabilitation","mixed reality","virtual reality","cerebrovascular accident","mirror visual feedback","2026-03-18",{"date":319,"type":46},"2026-03-20",{"date":321,"type":46},"2024-03-13",{"date":323,"type":22},"2026-07-31",{"name":325,"class":53},"Chang Gung Memorial Hospital",{"id":327,"slug":328,"hasResults":12,"nctId":329,"briefTitle":330,"officialTitle":331,"acronym":332,"eligibilityCriteria":333,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":334,"targetDuration":4,"studyType":192,"phases":4,"briefSummary":336,"conditions":337,"keywords":339,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":347,"lastUpdatePostDateStruct":348,"startDateStruct":350,"completionDateStruct":352,"leadSponsor":354,"locationsCount":54},"100297567","brain-blood-and-clot-or-tissue-registry-and-collaboration-100297567","NCT03153683","Brain, Blood And Clot or Tissue Registry And Collaboration","Brain, Blood And Clot or Tissue Registry And Collaboration (BACTRAC)","BACTRAC","Inclusion Criteria 1. All patients, Male or female, aged 18 years or older, undergoing cerebrovascular surgery\u002Fprocedure at the University of Kentucky.\n\nExclusion Criteria:\n\n1\\. Pregnant or breastfeeding females",{"count":335,"type":22},1000,"This is a prospective open enrollment biorepository to collect and evaluate blood and tissue collected during cerebrovascular procedures, which will then be used for the purposes of identifying biological markers, inflammatory cell infiltrates, and biological states in stroke and other cerebrovascular diseases in the human condition.\n\nThe study population will include up to 1000 subjects with cerebrovascular disease or suspected cerebrovascular disease. Male and female participants 18 years of age and older will be enrolled.\n\nThis protocol covers the procurement of biological samples from patients undergoing any cerebrovascular surgery and\u002For neurointerventional clinical procedure at University of Kentucky. Control participants will include patients undergoing non-emergent, elective diagnostic cerebral angiography as well as patients undergoing emergent angiogram cases.\n\nThis study represents the first time that tissue, clot and blood will be evaluated for the markers, proteins, and cytokines in human subjects undergoing cerebrovascular procedures.\n\nBy starting with the human condition, the investigators aim to minimize this loss in translation. Overall, this study will have a great impact on our knowledge of stroke pathology. In essence, this could fundamentally change not only how the investigators develop treatment strategies for the stroke patient population but allow us to individualize the treatment dependent on time after stroke, age, sex, and co-morbidities. Molecular techniques that are impractical when delivered systemically could be delivered locally to impede the early inflammation.\n\nThis research aims to advance understanding of cerebrovascular disease and to support the development of improved therapies.",[338,29],"Acute Ischemic Stroke",[340,341,36,342,343,344,345,346],"Acute","Ischemic","Biomarkers","Proteins","Inflammatory Cells","Acid\u002FBase Balance","cerebrovascular","2026-03-02",{"date":349,"type":46},"2026-03-04",{"date":351,"type":46},"2017-05-11",{"date":353,"type":22},"2029-12-28",{"name":355,"class":53},"Justin Fraser",{"id":357,"slug":358,"hasResults":12,"nctId":359,"briefTitle":360,"officialTitle":360,"acronym":361,"eligibilityCriteria":362,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":363,"targetDuration":4,"studyType":23,"phases":365,"briefSummary":366,"conditions":367,"keywords":369,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":381,"startDateStruct":383,"completionDateStruct":385,"leadSponsor":387,"locationsCount":4},"100618712","gravity-stroke-system-for-recanalization-of-large-vessel-occlusion-strokes-100618712","NCT07335185","Gravity Stroke System for Recanalization of Large Vessel Occlusion Strokes","GRASSROOT Reg","Inclusion Criteria:\n\n1. Subject has experienced an Acute Ischemic Stroke due to large intracranial vessel occlusion in at least one of the following intracranial vessels: internal carotid artery (ICA), M1and M2 segments of the middle cerebral artery (MCA), basilar, and vertebral artery.\n2. Subject has been or will be treated with Supernova and\u002For Neutron devices as the initial device used to remove the thrombus\n3. Subject is willing to participate in a 90-day follow-up visit.\n\nExclusion Criteria:\n\n* Concurrent participation in another mechanical neurothrombectomy device trial or any other clinical trial with an active treatment arm where the study procedure or treatment might confound the results of the registry.",{"count":364,"type":22},3000,[25],"Supernova and Neutron are endovascular mechanical revascularization devices indicated to restore blood flow by removing thrombus from a large intracranial vessel in patients experiencing an acute ischemic stroke within 24 hours of symptom onset or from last known well time.",[36,69,29,140,112,28,368],"Vascular Disease",[370,371,372,373,374,375,376,377,378,379,36,380],"Mechanical Thrombectomy","Brain","Brain Clot","Cerebral Ischemia","Brain Infarction","Neurovascular Intervention","Revascularization","Reperfusion","Stent Retriever","Supernova","Gravity Medical Technology",{"date":382,"type":46},"2026-01-13",{"date":384,"type":22},"2026-01-01",{"date":386,"type":22},"2030-12-31",{"name":388,"class":389},"Gravity Medical Technology, INC","INDUSTRY",{"id":391,"slug":392,"hasResults":12,"nctId":393,"briefTitle":394,"officialTitle":395,"acronym":4,"eligibilityCriteria":396,"healthyVolunteers":12,"sex":18,"minAge":305,"maxAge":221,"enrollmentInfo":397,"targetDuration":4,"studyType":23,"phases":399,"briefSummary":400,"conditions":401,"keywords":402,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":405,"lastUpdatePostDateStruct":406,"startDateStruct":408,"completionDateStruct":410,"leadSponsor":411,"locationsCount":54},"100617873","hybrid-stroke-rehab-with-mirror-priming-100617873","NCT07324278","Hybrid Stroke Rehab With Mirror Priming","Hybrid Stroke Rehabilitation With Mirror Priming","Inclusion Criteria:\n\n1. A first-ever unilateral stroke ≥3 months\n2. Age between 20 and 80 years\n3. Baseline Fugl-Meyer Assessment Upper Extremity (FMA-UE) score \\>10\n4. No severe spasticity in any joints of the affected arm\n5. Ability to follow the instructions\n6. No participation in other studies during the study period\n7. Willingness to provide informed written consent.\n\nExclusion Criteria:\n\n1\\. Serious medical problems or poor physical conditions that might be detrimental to study participation.",{"count":398,"type":22},81,[25],"This trial aims to examine the effects of enhanced mirror priming, overcoming the limitations of traditional mirror therapy, to achieve optimization and personalized intervention.",[30,36,29],[403,404],"Rehabilitation","Mirror Therapy","2025-12-23",{"date":407,"type":46},"2026-01-07",{"date":409,"type":22},"2025-12-30",{"date":386,"type":22},{"name":412,"class":53},"I-Shou University",{"id":414,"slug":415,"hasResults":12,"nctId":416,"briefTitle":417,"officialTitle":418,"acronym":419,"eligibilityCriteria":420,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":421,"targetDuration":423,"studyType":192,"phases":4,"briefSummary":424,"conditions":425,"keywords":433,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":441,"lastUpdatePostDateStruct":442,"startDateStruct":444,"completionDateStruct":446,"leadSponsor":448,"locationsCount":54},"100589453","cardiac-assessment-for-recurrent-stroke-risk-evaluation-in-atrial-fibrillation-100589453","NCT06954610","Cardiac Assessment for Recurrent Stroke Risk Evaluation in Atrial Fibrillation","CARE-AF: Cardiac Assessment for Recurrent Stroke Risk Evaluation in Atrial Fibrillation","CARE-AF","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Written informed consent (by patient, next of kin or legally authorised representative)\n* Permanent, persistent, or paroxysmal AF previously known or diagnosed during the index hospitalisation\n* Acute (≤7 days), symptomatic ischemic stroke\n\nExclusion Criteria:\n\n* Life expectancy \\\u003C1 year according to the opinion of the investigator\n* Patient is unlikely to attend follow-up visits",{"count":422,"type":22},500,"12 Months","Background\n\nAtrial fibrillation (AF) is the most common cardiac arrhythmia, affecting up to 10% of the elderly. Ischemic stroke is the main complication of AF and cardioembolism is one of the leading causes of ischemic stroke, accounting for approximately one third of cases. Oral anticoagulant therapy (OAC) is a cornerstone in stroke prevention in patients with AF. According to randomized controlled trials of direct oral anticoagulants, a residual risk of ischemic stroke of 1-2% per year for so-called \"breakthrough stroke\" remains, despite adequate intake of OAC. The majority (\\>70%) of these breakthrough strokes are cardioembolic in nature and only a minority are related to medication issues (e.g. non-compliance) or other, non-AF related etiologies. Stroke recurrence risk after such a breakthrough stroke markedly increases to 8-9% per year indicating a particularly high-risk situation. Why OAC fails in certain patients, but not in others remains as poorly understood, as does the reason why the subsequent risk of stroke is so high.\n\nCurrent risk stratification tools, such as the widely used CHA2DS2-VA(Sc)-score, fail to predict stroke risk in such a high-risk cohort, as they were intended to guide the initiation of OAC in low to moderate risk patients. In light of new therapeutic strategies currently being investigated, such as percutaneous left atrial appendage occlusion in patients with breakthrough strokes (ELAPSE - NCT05976685) or in AF-patients deemed high-risk (LAAOS IV - NCT05963698), improved risk stratification and characterization of high-risk AF patients is highly warranted.\n\nSeveral clinical factors, such as those reflected in the CHA2DS2-VA(Sc)-score, and especially a high AF-burden are associated with increased risk of cardioembolic stroke. Several cardiac serum biomarkers are thought to be surrogates not only of cardiac function, but also of cardioembolic risk. Reflecting ventricular and atrial wall tension, myocardial injury, oxidative stress and thrombogenicity, elevated NT-proBNP, MR-proANP, high-sensitive Troponin T and D-Dimers have all been associated with cardioembolic stroke in different AF and non-AF populations. As the main location of thrombus formation, the left atrium (LA) and more specifically its appendage (LAA) are of particular interest in the pathogenesis of cardioembolism. Pronounced LA-enlargement, compared to a normal-sized LA, correlates with an increased risk of cardioembolism in AF-patients. As over 80% of thrombi form within the LAA, several LAA-characteristics, such as slower LAA-flow velocity and larger LAA-orifice area have also been demonstrated to be associated with higher stroke risk. Although there is data on each one of these factors, they have only been investigated in low to moderate risk populations, such as AF-patients without prior stroke, OAC-naïve patients, or even within the general population as a whole. Their role in high-risk AF-patients and in breakthrough stroke is unknown.\n\nHypothesis\n\nThe investigators hypothesize that specific clinical factors, serum cardiac biomarkers and markers of LA- and LAA-morphology and function are associated with breakthrough stroke \u002F OAC-failure and may improve risk stratification.\n\nMethods\n\nCARE-AF is a single-center, prospective cohort study conducted at the Stroke Center of the Inselspital, University Hospital Bern, Switzerland. Patients with an index ischemic stroke and AF (breakthrough and non-breakthrough cases) will be enrolled. The investigators will collect clinical data, serum cardiac biomarkers and echocardiographic indices of the LA and LAA. All patients will receive standardized annual follow-ups until the end of the study, defined as 12 months after the inclusion of the last participant. The primary endpoint is ischemic stroke or systemic embolism during follow-up. First, in a cross-sectional design, the study will assess the association between serum cardiac biomarkers and echocardiographic indices among patients with breakthrough vs. non-breakthrough stroke as index event, applying multivariate regression models. Second, the investigators will perform a longitudinal analysis assessing the association between the variables mentioned above and breakthrough stroke as index event with the primary endpoint, using multivariate Cox regression models. The study aims to enroll a minimum of 500 patients, which provides sufficient power to detect a clinically meaningful adjusted hazard ratio for recurrent stroke of 1.5 with 80% power at an alpha level of 5%.\n\nConclusion\n\nThe results of this project will enhance understanding of the role of specific clinical factors, cardiac serum biomarkers and echocardiographic indices in the residual risk of stroke in patients with AF on anticoagulation therapy. They may improve current risk stratification and have the potential to help guide therapeutic decisions in high-risk situations considering evolving therapeutic possibilities.",[69,426,29,140,112,31,427,428,374,429,430,36,431,432],"Atrial Fibrillation","Arrhythmias, Cardiac","Heart Diseases","Brain Ischemia","Infarction Cerebral","Cardioembolic Stroke","Ischemia",[258,434,435,436,437,438,439,440],"Direct oral anticoagulation","Anticoagulation","Breakthrough stroke","Risk stratification","Atrial fibrillation","Anticoagulant therapy","Direct oral anticoagulant","2025-11-17",{"date":443,"type":46},"2025-11-20",{"date":445,"type":46},"2025-11-04",{"date":447,"type":22},"2028-06-30",{"name":449,"class":53},"Insel Gruppe AG, University Hospital Bern",{"id":451,"slug":452,"hasResults":12,"nctId":453,"briefTitle":454,"officialTitle":454,"acronym":455,"eligibilityCriteria":456,"healthyVolunteers":157,"sex":18,"minAge":191,"maxAge":457,"enrollmentInfo":458,"targetDuration":4,"studyType":23,"phases":460,"briefSummary":461,"conditions":462,"keywords":4,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":464,"lastUpdatePostDateStruct":465,"startDateStruct":467,"completionDateStruct":469,"leadSponsor":471,"locationsCount":54},"100518346","cerebrovascular-health-and-resilience-in-midlife-100518346","NCT06029348","Cerebrovascular Health and Resilience in Midlife","CHARM","Inclusion Criteria:\n\n* Able to attend 2 study visits at the University of Pittsburgh campus in Oakland (Pennsylvania)\n* Able to read and speak English\n\nExclusion Criteria:\n\n* Uncontrolled hypertension (systolic blood pressure \\>160 or diastolic blood pressure \\>100 mmHg)\n* Current use of anticonvulsant, anti-Parkinson, neuroleptic, or antipsychotic medications\n* Current use of glucocorticoids (e.g., oral prednisone) or ephedrine\n* Current chronic conditions of the lungs, liver and kidney, as well as cancer (chemotherapy and radiation) treatment in the past 12 months (allowances are made for non-melanoma skin cancer treatment, controlled asthma, and allergy inhalers)\n* Self-reported major neurological disorders or brain injuries (e.g., multiple sclerosis, cerebral palsy, major head injury)\n* Self-reported psychotic illnesses (mania, bipolar disorder, schizophrenia)\n* Current pregnancy or childbirth within the past 6 months\n* Suspected mild cognitive impairment or dementia\n* Self reported sleep apnea\n* Self-reported history of myocardial infarction, stroke, or revascularization procedures, as well as treatment for cardiac arrhythmias\n* Self-reported lack of comfort to undergo MRI testing\n* Presence of implants or objects that are unsafe for MRI (e.g., tattooed eyeliner), as well as any other contraindications that would prevent MRI testing\n* Self-reported lack of comfort to undergo the laboratory math task","59 Years",{"count":459,"type":22},450,[25],"This study examines cardiovascular responses to a brief psychological challenge under laboratory conditions among adult volunteers. The study volunteers are asked to complete two study sessions. In one session, the volunteers are asked to provide demographic and health-related information via questionnaires and an interview. In that session, volunteers would then be asked to undergo evaluations of their body composition, blood pressure, heart rate, and other signs of cardiovascular function and health. Lastly, volunteers would be asked to take part in a brief and challenging psychological task after a period of rest while cardiovascular activity is measured. In the other session, volunteers are asked to undergo magnetic resonance imaging and to complete neuropsychological tests of memory, attention, and processing speed. In addition to these two sessions, volunteers are asked to complete online questionnaires. The study is designed to examine associations between transient changes in cardiovascular activity induced by the psychological task, measures of overall cardiovascular health, and measures of cerebrovascular health measured by magnetic resonance imaging. Study results are expected to provide new information about the relationships between cardiovascular activity changes to psychological challenges and cardiovascular and cerebrovascular health in adults.",[463,30,29],"Psychological Stress","2025-09-22",{"date":466,"type":46},"2025-09-26",{"date":468,"type":46},"2023-10-17",{"date":470,"type":22},"2029-06-30",{"name":472,"class":53},"University of Pittsburgh",{"id":474,"slug":475,"hasResults":12,"nctId":476,"briefTitle":477,"officialTitle":478,"acronym":4,"eligibilityCriteria":479,"healthyVolunteers":12,"sex":18,"minAge":480,"maxAge":221,"enrollmentInfo":481,"targetDuration":4,"studyType":23,"phases":483,"briefSummary":484,"conditions":485,"keywords":487,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":495,"lastUpdatePostDateStruct":496,"startDateStruct":498,"completionDateStruct":500,"leadSponsor":502,"locationsCount":270},"100605825","phase-3-the-study-of-efficacy-and-safety-of-dimephosphon-in-acute-ischemic-stroke-100605825","NCT07167550","The Study of Efficacy and Safety of Dimephosphon® in Acute Ischemic Stroke","Multicenter, Randomized, Double-blind, Placebo-controlled Comparative Study of the Efficacy and Safety of the Drug Dimephosphon®, Concentrate for Solution for Intravenous Administration, 1 g, in Acute Ischemic Stroke Patients","Inclusion Criteria:\n\n1. Written informed consent was obtained from the patient or their legally authorized representative prior to study participation.\n2. Age 35-80.\n3. Patients must exhibit neurological manifestations consistent with acute ischemic stroke, with a documented onset-to-intervention interval ranging from 24 to 72 hours at the time of scheduled initial administration of the investigational drug.\n4. Verified by CT\u002FMRI current hemispheric ischemic stroke.\n5. NIHSS score ≥5 and ≤15 at screening.\n6. Ability to comply with all protocol-specified procedures, prohibitions, and restrictions.\n7. Willingness and ability to adhere to highly effective contraceptive methods as outlined in the study protocol.\n\nExclusion Criteria:\n\n1. Hemorrhagic stroke or hemorrhagic transformation of ischemic focus, traumatic brain injuries\n2. Vertebrobasilar stroke and\u002For development of acute insufficiency syndromes in the arteries of the vertebrobasilar system\n3. A patient with ischemic stroke who is a candidate for reperfusion therapy or who has undergone reperfusion therapy before participation in this study.\n4. The presence of anatomical abnormalities of the cerebral vessels (arteriovenous malformations, cavernous malformations, aneurysms, atresia of at least one of the extracranial arteries) according to the anamnesis or CT\u002FMRI data.\n5. Progression of neurological symptoms of stroke, defined as an increase in the NIHSS score by 4 points at the second assessment (immediately before randomization) from the value obtained at the first assessment (immediately after signing the informed consent form).\n6. Surgery on the carotid arteries less than 1 year before screening.\n7. History of stroke less than 1 year before screening.\n8. Myocardial infarction less than 6 months before screening.\n9. Chronic renal failure stage 2-3 (creatinine clearance less than 40 ml\u002Fmin).\n10. Pregnancy or lactation.\n11. Participation in another trial within 28 days prior to enrollment.\n12. Use of prohibited medications.","35 Years",{"count":482,"type":22},184,[107],"A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Dimephosphon® in acute ischemic stroke",[36,68,69,29,486],"Physiological Effects of Drugs",[488,489,490,491,492,493,68,69,494],"Neuroprotective Agents","Protective Agents","Neuroprotection","Anti-acidemic agents","Dimephosphon","Dimethyloxobutylphosphonyldimethylate","Antioxidants","2025-09-10",{"date":497,"type":46},"2025-09-11",{"date":499,"type":22},"2025-09-06",{"date":501,"type":22},"2026-04-30",{"name":503,"class":389},"Tatchempharmpreparaty, JSC",{"id":505,"slug":506,"hasResults":12,"nctId":507,"briefTitle":508,"officialTitle":509,"acronym":4,"eligibilityCriteria":510,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":221,"enrollmentInfo":511,"targetDuration":4,"studyType":23,"phases":512,"briefSummary":513,"conditions":514,"keywords":4,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":516,"lastUpdatePostDateStruct":517,"startDateStruct":519,"completionDateStruct":521,"leadSponsor":523,"locationsCount":54},"100579081","safety--feasibility-and-preliminary-efficacy-of-remote-ischemic-conditioning-in-patients-with-aneurysmal-subarachnoid-hemorrhage-after-aneurysm-clipping-100579081","NCT06819657","Safety , Feasibility and Preliminary Efficacy of Remote Ischemic Conditioning in Patients With Aneurysmal Subarachnoid Hemorrhage After Aneurysm Clipping","Remote Ischemic Conditioning for Safety, Feasibility, and Preliminary Efficacy in Patients With Aneurysmal Subarachnoid Hemorrhage After Aneurysm Clipping: An Open-Label, Evaluator-Blinded Randomized Controlled Trial","Inclusion Criteria:\n\n1. Imaging examination confirmed aneurysmal subarachnoid hemorrhage.\n2. Responsible aneurysms received craniotomy clipping within 24 hours.\n3. 18≤ age ≤80 years old.\n4. Informed consent of the participant or legally authorized representative\n\nExclusion Criteria:\n\n1. Patients with other types of cerebral hemorrhage.\n2. Prior neurological impairment (mRS Score \\>1) or mental illness may confuse neurological or functional assessment.\n3. Severe comorbidities with a life expectancy of less than 90 days.\n4. Refractory hypertension (systolic blood pressure 180\\>mmHg or diastolic blood pressure 110\\>mmHg).\n5. RIC contraindications: severe soft tissue injury of lower limbs.\n6. Simultaneously participate in another research program to study a different experimental therapy.\n7. Any condition that the investigator believes may increase the patient's risk.",{"count":5,"type":22},[25],"This study was designed to evaluate the safety and efficacy of remote ischemic conditioning (RIC) in patients with aneurysmal subarachnoid hemorrhage (aSAH) following surgical clipping.\n\nAneurysmal subarachnoid hemorrhage is a life-threatening condition that occurs when a cerebral aneurysm ruptures, causing bleeding into the subarachnoid space. Surgical clipping of the aneurysm is a standard procedure used to stop the bleeding and prevent re-rupture, thereby stabilizing the patient's condition.\n\nRemote ischemic conditioning (RIC) is a non-invasive treatment that involves using a blood pressure cuff to induce brief, temporary cycles of ischemia and reperfusion in a limb. Research suggests that this process may confer systemic protective effects, potentially improving recovery from brain injury or surgery. Although RIC has shown potential to improve outcomes in patients with other neurological conditions, its effect on patients with aSAH who undergo surgical clipping remains unclear.\n\nThis study will evaluate whether RIC can reduce complications, improve neurological function, and enhance overall recovery in these patients. The findings will help determine whether RIC should be incorporated into the standard treatment regimen for aSAH.",[515,29,140,36,30,31,28],"Subarachnoid Hemorrhage, Aneurysmal","2025-09-08",{"date":518,"type":46},"2025-09-09",{"date":520,"type":46},"2025-03-10",{"date":522,"type":22},"2026-03-30",{"name":524,"class":53},"Beijing Tiantan Hospital",{"id":526,"slug":527,"hasResults":12,"nctId":528,"briefTitle":529,"officialTitle":530,"acronym":531,"eligibilityCriteria":532,"healthyVolunteers":12,"sex":18,"minAge":533,"maxAge":534,"enrollmentInfo":535,"targetDuration":4,"studyType":23,"phases":537,"briefSummary":539,"conditions":540,"keywords":541,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":545,"lastUpdatePostDateStruct":546,"startDateStruct":548,"completionDateStruct":550,"leadSponsor":552,"locationsCount":241},"100245330","phase-4-blood-pressure-reduction-to-limit-the-evolution-of-vascular-brain-lesions-in-elderly-individuals-100245330","NCT02472028","Blood Pressure Reduction to Limit the Evolution of Vascular Brain Lesions in Elderly Individuals","LEukoaraiosis and blOod Pressure Reduction in OLD People","LEOPOLD","Inclusion Criteria:\n\n* 60 to 88 years old patients;\n* Patient with cognitive complaint with MMSE ≥ 20performed within 6 months prior to enrollment (with or without dementia)\n* Patient with a socio-educational level ≥ 3\n* Presence of hyperintensities of moderate to high grade on the last MRI or old scan (grades C and D on the modified Scheltens scale, grades 2\u002F3 Fazekas).\n* Hypertension defined by a Systolic Blood Pressure (SBP) and \u002F or a Diastolic Blood Pressure (DBP) ≥ 140\u002F90 mmHg, treated or not\n* Affiliation to a social security system\n* Informed consent given, signed consent\n\nExclusion Criteria:\n\n* Presence of severe orthostatic hypotension defined as a decrease of 30 mmHg in SBP standing within 3 minutes\n* Contraindication to MRI (presence of ferromagnetic foreign body (especially some intracranial clips, some heart valves, intraocular foreign bodies, metal prosthesis), subject carrying pacemaker, claustrophobic participants)\n* Severe diseases associated with a life expectancy of less than 3 months;\n* Major physical impairments that can interfere with the feasibility of the tests (sight, hearing ...)\n* Presence of another dementia different than Alzheimer's disease vascular dementia or mixed dementia,\n* Persons under guardianship;\n* Secondary hypertension: renovascular hypertension, primary aldosteronism, pheochromocytoma ...;\n* Patient already receiving 4 or more antihypertensive drugs at maximum dosage\n* Patient participating in another clinical research study on drug requiring exclusion period\n* severe renal impairment","60 Years","88 Years",{"count":536,"type":22},820,[538],"PHASE4","The purpose of the study is to test the hypothesis of slowing the progression of White Matter Lesions (WML) by lowering blood pressure (BP) in patients with cognitive complaints and a moderate to high grade of WML on brain MRI.",[29],[29,36,542,543,544],"Antihypertensive Agents","Arterial Pressure","Memory Disorders","2025-09-04",{"date":547,"type":46},"2025-09-05",{"date":549,"type":46},"2015-09",{"date":551,"type":22},"2028-09-11",{"name":553,"class":53},"Assistance Publique - Hôpitaux de Paris",{"id":555,"slug":556,"hasResults":12,"nctId":557,"briefTitle":558,"officialTitle":559,"acronym":560,"eligibilityCriteria":561,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":562,"targetDuration":4,"studyType":192,"phases":4,"briefSummary":564,"conditions":565,"keywords":568,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":572,"lastUpdatePostDateStruct":573,"startDateStruct":574,"completionDateStruct":576,"leadSponsor":578,"locationsCount":54},"100525407","precision-medicine-in-stroke-evolution-of-plasma-brain-derived-tau-in-acute-stroke-100525407","NCT06121336","PRecisiOn Medicine In StrokE: Evolution of Plasma Brain-Derived Tau in Acute Stroke","PRecisiOn Medicine In StrokE Study on the Evolution of Plasma Brain-Derived Tau in 100 Patients With Acute Ischemic Stroke","PROMISE-BD-100","Inclusion Criteria:\n\n* clinical diagnosis of acute ischemic stroke\n* presentation within 9 hours of symptom onset\n* large- or medium-vessel occlusion (i.e. an occlusion of the ICA, MCA \\[segments M1-M4\\], ACA \\[segments A1-A3\\], basilar artery, or PCA \\[segments P1 to P3\\]) confirmed by CT or MRI angiography\n* at least 18 years of age\n* written informed consent\n\nExclusion Criteria:\n\n* CT or MRI showing intracranial hemorrhage upon admission\n* A history of ischemic stroke, subarachnoid hemorrhage, intracerebral hemorrhage, subdural hematoma, epidural hematoma, CNS tumor, meningitis, or encephalitis within the last three months\n* severe renal dysfunction (eGFR \\\u003C 30ml\u002Fmin\u002F1.73m2)\n* dementia\n* pre-stroke disability defined as a premorbid modified Rankin Scale score \\> 1",{"count":563,"type":22},100,"The investigators recently identified Brain-derived tau (BD-tau) as a sensitive blood-based biomarker for brain injury in acute ischemic stroke: in patients with acute ischemic stroke, plasma BD-tau was associated with imaging-based metrics of brain injury upon admission, increased within the first 24 hours in correlation with infarct progression, and at 24 hours was superior to final infarct volume in predicting 90-day functional outcome. While informing on the relation of BD-tau with imaging-based metrics of brain injury, this cross-sectional study was restricted to BD-tau assessments upon admission and at day 2 and could not inform on key characteristics of the evolution of plasma BD-tau, including when exactly it starts to rise, how long it continues to rise, and how it is determined by infarct characteristics as well as comorbidities. Here, the investigators aim to assess plasma BD-tau every hour from admission to 48 hours after onset to evaluate the hypothesis that BD-tau rises immediately after onset and plateaus between three and 48 hours after onset.",[36,566,567,29,140,112,429,28],"Stroke, Acute","Stroke, Ischemic",[36,569,570,571],"Brain injury","Biomarker","Pathophysiology","2025-09-02",{"date":545,"type":46},{"date":575,"type":46},"2023-03-01",{"date":577,"type":22},"2026-09-30",{"name":579,"class":53},"Ludwig-Maximilians - University of Munich",{"id":581,"slug":582,"hasResults":12,"nctId":583,"briefTitle":584,"officialTitle":585,"acronym":586,"eligibilityCriteria":587,"healthyVolunteers":157,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":588,"targetDuration":589,"studyType":192,"phases":4,"briefSummary":590,"conditions":591,"keywords":594,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":600,"lastUpdatePostDateStruct":601,"startDateStruct":603,"completionDateStruct":605,"leadSponsor":607,"locationsCount":54},"100603752","environmental-pollutants-and-neurological-disorders-100603752","NCT07140601","Environmental Pollutants and Neurological Disorders","Environmental Pollutants and Neurological Disorders: Clinical and Mechanistic Study","CLEAN","Inclusion Criteria:\n\n* 18 years of age or older;\n* Able to give informed consent to participate in the research.\n\nExclusion Criteria:\n\n* Refusal to participate.\n* Pregnant or breastfeeding woman.",{"count":422,"type":22},"24 Months","Environmental pollutants have emerged as a major global health concern, with growing evidence linking exposure to both traditional contaminants such as heavy metals (lead, mercury, cadmium, arsenic) and novel pollutants-including micro- and nanoplastics, per- and polyfluoroalkyl substances (PFAS), antibiotics, and endocrine-disrupting chemicals-to adverse neurological outcomes. These pollutants can cross or disrupt the blood-brain barrier, accumulate in neural tissue, and trigger oxidative stress, inflammation, epigenetic modifications, and metabolic reprogramming.\n\nBrain tumours and cerebrovascular diseases represent two major categories of neurosurgical disorders with high morbidity and mortality. However, their interaction with environmental pollutant exposure remains poorly understood. Recent studies suggest that pollutant-induced molecular alterations, such as aberrant DNA methylation, lipid metabolism disruption, and neurovascular endothelial dysfunction, may contribute to tumour initiation, malignant progression, aneurysm formation, and stroke occurrence.\n\nGiven the increasing human exposure to these pollutants and the lack of large-scale clinical data, it is urgent to establish a systematic investigation in neurosurgical patients. This study aims to profile pollutant exposure (heavy metals, PFAS, microplastics, and other novel contaminants) using multi-biospecimen analysis (blood, urine, hair, tumour and peri-tumour tissues), and to explore their mechanistic links to the pathogenesis of brain tumours and cerebrovascular diseases. The findings are expected to provide new evidence for understanding environment-brain interactions and to identify potential biomarkers for disease risk stratification and prevention.",[29,592,593],"Brain Tumours","Alzheimer Dementia",[595,596,597,598,599],"Environmental Pollutants","Exposomics","Pathogenic Mechanisms","Neurological Disorders","Neurosurgical Patients","2025-08-22",{"date":602,"type":46},"2025-08-24",{"date":604,"type":46},"2025-08-01",{"date":606,"type":22},"2027-08-01",{"name":524,"class":53},{"id":609,"slug":610,"hasResults":12,"nctId":611,"briefTitle":612,"officialTitle":613,"acronym":614,"eligibilityCriteria":615,"healthyVolunteers":12,"sex":18,"minAge":616,"maxAge":221,"enrollmentInfo":617,"targetDuration":4,"studyType":23,"phases":619,"briefSummary":620,"conditions":621,"keywords":622,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":627,"lastUpdatePostDateStruct":628,"startDateStruct":630,"completionDateStruct":632,"leadSponsor":633,"locationsCount":54},"100555084","daphnetin-capsule-in-the-treatment-of-vascular-cognitive-impairment-without-dementia-100555084","NCT06507488","Daphnetin Capsule In the Treatment of VaScular COgnitive Impairment Without Dementia","Daphnetin Capsule In the Treatment of VaScular COgnitive Impairment Without Dementia - A Randomized, Double-blind, Placebo-controlled Study","DISCO","Inclusion Criteria:\n\n1. Be 50-80 years of age (both ends included)\n2. Have a complaint of cognitive impairment involving memory and\u002For other cognitive domains that has persisted for at least 3 months\n3. Have a cognitive level that is neither normal nor demented according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Criteria ( DSM-V criteria）, a Montreal Cognitive Assessment (MoCA scale) score \\\u003C26 and ≥18, and a Clinical Dementia Rating (CDR) scale score of ≥0.5 in at least one domain and an overall CDR score ≤1\n4. Have a cognitive level that is neither normal nor demented according to DSM-V criteria, a MoCA scale score \\\u003C26 and ≥18, and a CDR scale score of ≥0.5 in at least one domain and an overall CDR score ≤1\n5. Voluntarily participate in this study and sign an informed consent form.\n\nExclusion Criteria:\n\n1. Previously diagnosed dementia; vascular cognitive impairment not associated with a condition other than dementia that may affect cognition\n2. Acute stroke event within 6 months\n3. Previously diagnosed hereditary or inflammatory small vessel disease\n4. Presence of congenital mental retardation and severe neurological or psychiatric disorders\n5. Illiteracy or severe visual or hearing impairment, severe aphasia, and other factors that may preclude cooperation with neuropsychological evaluation\n6. Associated depression (Hamilton Depression Scale score ≥ 17), or other unrelated serious mental illness (schizophrenia, bipolar disorder, or delirium)\n7. Combined severe cardiac, pulmonary, and renal insufficiency (creatinine \\> 2.0 mg\u002Fdl or 177 μ mol\u002FL), and severe hepatic impairment (aminotransferases more than 3 times normal)\n8. Alcoholism, drug addiction, or ongoing use of medications that affect cognitive assessment, such as tranquilizers, sleeping pills, puberty pills, and cholinergics\n9. Malignant tumors that have been clearly diagnosed, vital organ failure\n10. Those with bleeding tendency after surgery\n11. Pregnant and lactating women are prohibited\n12. Severe hypertension (Systolic Blood Pressure(SBP)≥160mmHg and\u002For Diastolic Blood Pressure(DBP)≥110mmHg) is prohibited\n13. Previous allergy or intolerance to the ingredients of Reserpine\n14. The subject does not have a stable and reliable caregiver or the caregiver is unable to assist the subject in participating in the study\n15. Patients who have participated in other interventional clinical studies within the last 3 months or are currently participating in other interventional clinical studies.","50 Years",{"count":618,"type":22},206,[25],"The purpose of this clinical trial is to understand and evaluate the clinical efficacy and safety of Daphnetin Capsule in patients with vascular cognitive impairment. Changes in the Vascular Dementia Assessment Scale-cog(VADAS-cog) at 6 months were evaluated. Although Daphnetin has a dual neurovascular protective effect, however, there is still a lack of relevant high-quality studies on its role in patients with vascular cognitive impairment, especially in patients with vascular cognitive impairment in non-dementia (VCI-ND), whether it has a role in improving cognitive status needs to be urgently explored in high-quality clinical studies. Researchers are comparing Daphnetin to placebo (a drug-free analog) to see if Daphnetin is effective in treating vascular cognitive impairment. Participants will take either Daphnetin or placebo daily for six months, with follow-up visits every three months and completion of a case report form.",[29],[623,624,625,626],"Vascular Cognitive Impairment No Dementia","Daphnetin","Effectiveness","safety","2025-08-21",{"date":629,"type":46},"2025-08-28",{"date":631,"type":46},"2025-07-07",{"date":501,"type":22},{"name":634,"class":53},"First People's Hospital of Shenyang",{"id":636,"slug":637,"hasResults":12,"nctId":638,"briefTitle":639,"officialTitle":640,"acronym":641,"eligibilityCriteria":642,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":643,"targetDuration":645,"studyType":192,"phases":4,"briefSummary":646,"conditions":647,"keywords":649,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":657,"lastUpdatePostDateStruct":658,"startDateStruct":660,"completionDateStruct":662,"leadSponsor":664,"locationsCount":54},"100548261","the-correlation-of-intracranial-artery-calcification-and-outcomes-of-mechanical-thrombectomy-100548261","NCT06418698","The Correlation of Intracranial Artery Calcification and Outcomes of Mechanical Thrombectomy","The Prediction of Intracranial Artery Calcification on Adverse Outcomes of Large Vessel Occlusive, Acute Ischemic Stroke Patients After Mechanical Thrombectomy: A Prospective Cohort, Observational Study","CAIS-MT","Inclusion Criteria:\n\n* Male or non-pregnant women with acute stroke symptoms aged over 18 years.\n* Occlusion of the intracranial internal carotid artery, the middle cerebral artery, the anterior cerebral artery, the posterior cerebral artery, basilar artery and intracranial vertebral artery confirmed by CT, MR angiography, or digital subtraction angiography.\n* No absolute contraindication to iodinated contrast media.\n* Planned treatment with EVT by clinical care team.\n* Informed consent obtained from patients or their legal representatives.\n* Willing to be followed up as required by the clinical study protocol.\n\nExclusion Criteria:\n\n* Acute ischemic stroke occurs over 24 hours of time last known well.\n* Neurologic deficits caused by diagnoses other than ischemic stroke, such as intracerebral hemorrhage, subarachnoid hemorrhage, or intracranial tumors.\n* With other underlying factors leading to IAC, such as hyperthyroidism, end-stage renal disease, long-term oral intake of vitamin K antagonist(Warfarin), chronic vitamin D deficiency or overdose, persistent hypomagnesemia, persistent hypercalcemia, persistent hyperphosphatemia and high oral calcium intake.\n* Lack of non-contract CT images on admission and significant artifacts in CT images preventing IAC measurement.\n* Severe renal insufficiency (estimated glomerular filtration rate \\\u003C 30ml\u002Fmin or serum creatinine \\> 220μmol\u002FL (2.5mg\u002Fdl)).\n* Previous cerebrovascular intervention treatment or craniotomy.",{"count":644,"type":22},434,"3 Years","CAIS-MT is a single-center, prospective cohort study, to evaluate the correlation between outcomes of endovascular treatment(EVT) and intracranial artery calcification(IAC) in patients with acute ischemic stroke due to large or medium vessel occlusion.",[566,69,31,112,28,36,140,29,648],"Intracranial Arterial Calcification",[650,651,652,653,654,655,656],"Acute ischemic stroke","Large vessel occlusion","Mechanical thrombectomy","Endovascular treatment","Agatston score","Prospective cohort study","Intracranial atherosclerotic disease","2025-07-24",{"date":659,"type":46},"2025-07-28",{"date":661,"type":46},"2024-03-28",{"date":663,"type":22},"2029-06",{"name":665,"class":53},"Zhujiang Hospital",{"id":667,"slug":668,"hasResults":12,"nctId":669,"briefTitle":670,"officialTitle":671,"acronym":672,"eligibilityCriteria":673,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":221,"enrollmentInfo":674,"targetDuration":4,"studyType":23,"phases":676,"briefSummary":677,"conditions":678,"keywords":681,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":686,"lastUpdatePostDateStruct":687,"startDateStruct":688,"completionDateStruct":690,"leadSponsor":692,"locationsCount":693},"100599727","statins-for-treatment-of-primary-intracerebral-hemorrhage-100599727","NCT07088250","Statins for Treatment of Primary Intracerebral Hemorrhage","Statins for Treatment Of Primary IntraCerebral Hemorrhage (STOP ICH)","STOP ICH","Inclusion Criteria:\n\n* Patients with a diagnosis of spontaneous intracerebral hemorrhage (ICH) confirmed by computed tomography (CT);\n* Age 18-80 years;\n* Hematoma located in the supratentorial region;\n* Time from symptom onset or last known well to baseline CT ranging from 3 to 24 hours;\n* Atorvastatin treatment can be initiated within 48 hours of symptom onset or last known well;\n* Glasgow Coma Scale (GCS) score ≥9;\n* Baseline hematoma volume of 5-35 mL;\n* Signed informed consent obtained.\n\nExclusion Criteria:\n\n* ICH secondary to trauma, tumor, aneurysm, arteriovenous malformation (AVM), vascular anomaly, hemorrhagic transformation of infarction, cerebral venous thrombosis, or anticoagulant-related ICH;\n* Patients who have undergone or are scheduled for immediate surgical intervention;\n* Pregnancy or lactation;\n* Use of oral anticoagulants within 1 month prior to symptom onset;\n* Pre-stroke mRS \\>1;\n* Known allergy to statins, active liver disease, liver dysfunction, or rhabdomyolysis;\n* Known terminal illness with a pre-stroke life expectancy of less than three months, or patients with planned withdrawal of care.",{"count":675,"type":22},264,[25],"The STOP ICH trial is a multicenter, prospective, randomized, open-label, blinded end-point (PROBE) study designed to assess the efficacy and safety of atorvastatin in patients with intracerebral hemorrhage (ICH) presenting within 3 to 24 hours of symptom onset.",[29,33,679,680],"Intracranial Hemorrhage","Intracerebral Haemorrhage",[682,683,684,685],"Intracerebral hemorrhage","Treatment","Atorvastatin","Outcome","2025-07-20",{"date":659,"type":46},{"date":689,"type":46},"2023-05-06",{"date":691,"type":22},"2026-12-31",{"name":269,"class":53},22,{"id":695,"slug":696,"hasResults":12,"nctId":697,"briefTitle":698,"officialTitle":699,"acronym":700,"eligibilityCriteria":701,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":221,"enrollmentInfo":702,"targetDuration":4,"studyType":23,"phases":703,"briefSummary":704,"conditions":705,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":631,"lastUpdatePostDateStruct":707,"startDateStruct":709,"completionDateStruct":711,"leadSponsor":713,"locationsCount":54},"100570750","remote-ischemic-conditioning-for-efficacy-in-patients-with-aneurysmal-subarachnoid-hemorrhage-100570750","NCT06711302","Remote Ischemic Conditioning for Efficacy in Patients With Aneurysmal Subarachnoid Hemorrhage","Remote Ischemic Conditioning for Efficacy in Patients With Aneurysmal Subarachnoid Hemorrhage: a Multi-center, Randomized, Double-blind, Sham-controlled, Parallel-group Trial","REPAIR","Inclusion Criteria:\n\n1. Patients with aneurysmal subarachnoid hemorrhage confirmed by imaging examination (diagnosed by computed tomography and confirmation of an intracranial aneurysm by CT angiography or digital subtraction angiography);\n2. The Hunt-Hess grade is 2-3 at admission;\n3. Onset of aneurysmal subarachnoid hemorrhage ≤72 hours;\n4. The responsible aneurysm has been treated by endovascular interventional therapy;\n5. 18≤ age ≤80 years old;\n6. Informed consent must be obtained from participants or legally authorized representatives.\n\nExclusion Criteria:\n\n1. Patients with other intracerebral hemorrhage or other types of subarachnoid hemorrhage;\n2. Previous neurological deficits (mRS Score ≥1) or psychiatric disorders that can confound neurological or functional assessments;\n3. With severe comorbidities and a life expectancy of less than 90 days;\n4. Refractory hypertension (Systolic blood pressure\\> 180 mmHg or diastolic blood pressure \\>110 mmHg);\n5. Contraindications of RIC: severe soft tissue injury of the lower limbs, etc;\n6. Concurrent participation in another protocol investigating a different experimental therapy;\n7. Any condition that the investigator believes may increase the patient's risk.",{"count":422,"type":22},[25],"Several recent large-scale clinical trials aimed at improving subarachnoid hemorrhage(SAH) outcomes have concluded with negative results, failing to enhance the prognosis for these patients. Consequently, there is an urgent demand for novel treatment strategies and approaches to address the challenges posed by SAH.\n\nRemote ischemic conditioning(RIC) has gained considerable attention in the treatment of stroke, particularly ischemic stroke, with numerous studies demonstrating its potential to enhance neurological outcomes compared to conventional treatments alone.RIC for the treatment of SAH is an investigative strategy in its initial stages. The neuroprotective effects of RIC, particularly its potential to preserve cranial nerve function and ameliorate neurological deficits, confer significant value in the treatment of SAH patients.\n\nThe precise manner in which SAH patients may benefit from RIC treatment, and the mechanisms by which it improves neurological function, remain to be fully understood. Consequently, randomized controlled trials are necessary to validate the efficacy of RIC in this patient population and to delineate the optimal therapeutic protocols for its application.\n\nBased on the above discussion, this study aims to explore the efficacy and safety of RIC in the treatment of SAH.",[706,29,140,36,30,31,28],"Subarachnoid Hemorrhage",{"date":708,"type":46},"2025-07-10",{"date":710,"type":22},"2025-07-01",{"date":712,"type":22},"2026-04-01",{"name":524,"class":53},{"id":715,"slug":716,"hasResults":12,"nctId":717,"briefTitle":718,"officialTitle":718,"acronym":719,"eligibilityCriteria":720,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":721,"targetDuration":722,"studyType":192,"phases":4,"briefSummary":723,"conditions":724,"keywords":727,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":730,"lastUpdatePostDateStruct":731,"startDateStruct":733,"completionDateStruct":735,"leadSponsor":737,"locationsCount":54},"100595569","a-real-world-study-on-ultrasound-based-screening-and-integrated-therapeutic-strategies-for-patients-with-concomitant-coronary-and-cervicocephalic-artery-stenosis-100595569","NCT07034157","A Real-World Study on Ultrasound-Based Screening and Integrated Therapeutic Strategies for Patients With Concomitant Coronary and Cervicocephalic Artery Stenosis","ANGEL-UNIFY","Inclusion Criteria:\n\n1. Age ≥18 years;\n2. Patients with coronary artery disease scheduled to undergo elective percutaneous coronary intervention (PCI) on the following day.\n\nExclusion Criteria:\n\n1. The expected survival is less than 1 years;\n2. Simultaneously merge other serious diseases;",{"count":335,"type":22},"1 Year","This prospective observational cohort study aims to investigate the prevalence and clinical significance of head and neck arterial stenosis in patients with coronary artery disease (CAD) undergoing or scheduled for percutaneous coronary intervention (PCI). Using Doppler ultrasound as the primary screening tool, the study will assess the degree of stenosis and evaluate the impact of different combined treatment strategies on patient outcomes. The research will provide real-world evidence to optimize integrated care approaches for patients with comorbid cardiovascular and cerebrovascular diseases.",[725,726,29],"Coronary Artery Disease","Carotid Artery Stenosis",[725,726,728,729],"Doppler Ultrasound","Combined Vascular Intervention","2025-06-15",{"date":732,"type":46},"2025-06-24",{"date":734,"type":46},"2025-06-09",{"date":736,"type":22},"2026-12-30",{"name":738,"class":53},"Beijing Anzhen Hospital"]